A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia
Primary Purpose
Functional Dyspepsia
Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Motilitone®
A-Cilin®, Clari® and Pantoline®
Sponsored by
About this trial
This is an interventional treatment trial for Functional Dyspepsia
Eligibility Criteria
Inclusion Criteria:
- Roman III criteria
- One or more conditions are applied: epigastric pain, epigastric burning, bothersome, postprandial fullness or early satiety
- No organic lesion
- Helicobacter pylori infection
Exclusion Criteria:
- has taken prokinetics, H2 antagonists, PPIs, NSAIDs, anticholinergics, antibiotics, antidepressants, anticoagulants within a month
- had a surgery that might affect gastrointestinal motility
Sites / Locations
- Chung-Ang University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
H.Pylori eradication therapy
Motilitone®
Arm Description
A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
Outcomes
Primary Outcome Measures
Volunteer global assessment of improvement rate of functional dyspepsia by using 5-Likert scale
5-Likert scale
deteriorated
not changed
moderately improved
markedly improved
symptom-free
Secondary Outcome Measures
Volunteer global assessment by using 5-Likert scale
The improvement rate of 4 types of dyspepsia symptoms
The change of each score and total score of dyspeptic symptoms
Assessment of NDI-K Quality of Life
The proportion of the patients who answered "yes for the question about symptom improvement
Full Information
NCT ID
NCT02162316
First Posted
June 11, 2014
Last Updated
June 23, 2014
Sponsor
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02162316
Brief Title
A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia
Official Title
A Multicenter, Randomized, Double-blind Comparative Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia
Study Type
Interventional
2. Study Status
Record Verification Date
June 2014
Overall Recruitment Status
Unknown status
Study Start Date
July 2014 (undefined)
Primary Completion Date
June 2015 (Anticipated)
Study Completion Date
October 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a clinical study to evaluate the efficacy between Helicobacter pylori Eradication therapy and Motilitone in Functional Dyspepsia
Detailed Description
This is a multicenter, randomized, double-blind comparative clinical study to evaluate the efficacy between Helicobacter pylori Eradication therapy and Motilitone in Functional Dyspepsia
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Dyspepsia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
136 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
H.Pylori eradication therapy
Arm Type
Active Comparator
Arm Description
A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
Arm Title
Motilitone®
Arm Type
Experimental
Arm Description
30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
Intervention Type
Drug
Intervention Name(s)
Motilitone®
Intervention Type
Drug
Intervention Name(s)
A-Cilin®, Clari® and Pantoline®
Primary Outcome Measure Information:
Title
Volunteer global assessment of improvement rate of functional dyspepsia by using 5-Likert scale
Description
5-Likert scale
deteriorated
not changed
moderately improved
markedly improved
symptom-free
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Volunteer global assessment by using 5-Likert scale
Time Frame
6 weeks
Title
The improvement rate of 4 types of dyspepsia symptoms
Time Frame
12 weeks
Title
The change of each score and total score of dyspeptic symptoms
Time Frame
6, 12 weeks
Title
Assessment of NDI-K Quality of Life
Time Frame
6,12 weeks
Title
The proportion of the patients who answered "yes for the question about symptom improvement
Time Frame
6, 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Roman III criteria
One or more conditions are applied: epigastric pain, epigastric burning, bothersome, postprandial fullness or early satiety
No organic lesion
Helicobacter pylori infection
Exclusion Criteria:
has taken prokinetics, H2 antagonists, PPIs, NSAIDs, anticholinergics, antibiotics, antidepressants, anticoagulants within a month
had a surgery that might affect gastrointestinal motility
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jae Gyu Kim, M.D., Ph.D
Phone
82-2-6299-3147
Email
jgkimd@cau.ac.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Su Jin Hong, M.D., Ph.D.
Organizational Affiliation
Soonchunhyang University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gwang Ha Kim, M.D., Ph.D.
Organizational Affiliation
Busan National University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sang Gyun Kim, M.D., Ph.D
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hyun Soo Kim, M.D., Ph.D
Organizational Affiliation
Chonnam National University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Seong-Woo Jeon, M.D., Ph.D
Organizational Affiliation
Kyungpook National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chung-Ang University Hospital
City
Seoul
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jae Gyu Kim, M.D., Ph.D
12. IPD Sharing Statement
Learn more about this trial
A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia
We'll reach out to this number within 24 hrs